Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro

Antiviral Research

Volumn 139, Issue , 2017, Pages 25-31

  Liu, Yang ^a   Miller, Michael D ^a   Kitrinos, Kathryn M ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Drug susceptibility; HBV genotype; HBV resistance; Tenofovir alafenamide (TAF)

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR ALAFENAMIDE; ADENINE; ANTIVIRUS AGENT; GS-7340; PRODRUG;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; DNA REPLICATION; EC50; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B VIRUS GENOTYPE A; HEPATITIS B VIRUS GENOTYPE B; HEPATITIS B VIRUS GENOTYPE C; HEPATITIS B VIRUS GENOTYPE D; HEPATITIS B VIRUS GENOTYPE E; HEPATITIS B VIRUS GENOTYPE F; HEPATITIS B VIRUS GENOTYPE G; HEPATITIS B VIRUS GENOTYPE H; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROMOTER REGION; SITE DIRECTED MUTAGENESIS; STOP CODON; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; CHEMISTRY; DRUG EFFECTS; GENETICS; HEP-G2 CELL LINE; PHENOTYPE; PHYSIOLOGY; VIROLOGY;

ADENINE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HEP G2 CELLS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MUTAGENESIS, SITE-DIRECTED; PHENOTYPE; PRODRUGS; VIRUS REPLICATION;

EID: 85007414156     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.12.012     Document Type: Article

References (42)

1. Arauz-Ruiz, P., Norder, H., Robertson, B.H., Magnius, L.O., Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J. General Virology 83:Pt 8 (2002), 2059–2073 Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12124470.
2. Bartholomeusz, A., Tehan, B.G., Chalmers, D.K., Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir. Ther. 9:2 (2004), 149–160.
3. Berg, T., Zoulim, F., Moeller, B., Trinh, H., Marcellin, P., Chan, S., …, Manns, M., Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J. Hepatology 60:4 (2014), 715–722, 10.1016/j.jhep.2013.11.024.
4. Birkus, G., Kutty, N., He, G.X., Mulato, A., Lee, W., McDermott, M., Cihlar, T., Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases. Mol. Pharmacol. 74:1 (2008), 92–100 Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18430788.
5. Birkus, G., Wang, R., Liu, X.H., Kutty, N., MacArthur, H., Cihlar, T., …, McDermott, M., Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. Antimicrob. Agents Chemother. 51:2 (2007), 543–550, 10.1128/Aac.00968-06.
6. Buster, E.H., Flink, H.J., Cakaloglu, Y., Simon, K., Trojan, J., Tabak, F., …, Janssen, H.L., Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 135:2 (2008), 459–467 Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18585385.
7. Buti, M., Gane, E., Seto, W.K., Chan, H.L.Y., Chuang, W.L., Stepanova, T., …, Marcellin, P., A Phase 3 Study of Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate in Patients with HBeAg-negative, Chronic Hepatitis B: Week 48 Efficacy and Safety Results [Presentation GS-06]. Paper Presented at the European Association for the Study of the Liver (EASL), Barcelona, Spain, 2016, 13–17 April.
8. Chan, H.L.Y., Fung, S., Seto, W.K., Chuang, W.L., Chen, C.Y., Kim, H.J., …, Agarwal, K., A Phase 3 Study of Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate in Patients with HBeAg-positive, Chronic Hepatitis B: Week 48 Efficacy and Safety Results [Presentation GS12]. Paper Presented at the European Association for the Study of the Liver (EASL), Barcelona, Spain, 2016, 13–17 April.
9. Corsa, A.C., Liu, Y., Flaherty, J.F., Mitchell, B., Fung, S.K., Gane, E., …, Kitrinos, K.M., No resistance to tenofovir disoproxil fumarate through 96 Weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin. Gastroenterology Hepatology 12 (2014), 2106–2112, 10.1016/j.cgh.2014.05.024.
10. Flink, H.J., van Zonneveld, M., Hansen, B.E., de Man, R.A., Schalm, S.W., Janssen, H.L., Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am. J. Gastroenterology 101:2 (2006), 297–303 Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16454834.
11. Fung, S., Kwan, P., Fabri, M., Horban, A., Pelemis, M., Hann, H.W., …, Gane, E., Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 146:4 (2014), 980–988, 10.1053/j.gastro.2013.12.028 e981.
12. Gane, E., Benhamou, Y., Gladysz, A., Zeuzem, S., Germanidis, G., Heathcote, J., …, Snow-Lampart, A., Lack of Influence of Baseline Genotype on Antiviral Response in Subjects with Chronic Hepatitis B Infection Receiving Tenofovir DF 300 MG QD for 1 Year [poster #2780]. Paper Presented at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, 2008.
13. Günther, S., Li, B.-C., Miska, S., Krüger, D.H., Meisel, H., Will, H., A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J. Virology 69:9 (1995), 5437–5444 Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7636989.
14. Hadziyannis, S.J., Tassopoulos, N., Heathcote, E.J., Chang, T.-T., Kitis, G., Rizzetto, M., for the Adefovir Dipivoxil 438 Study Group, Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 348:9 (2003), 800–807.
15. Hadziyannis, S.J., Tassopoulos, N.C., Heathcote, E.J., Chang, T.T., Kitis, G., Rizzetto, M., …, Chuck, S.L., Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131:6 (2006), 1743–1751 Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17087951.
16. Janssen, H.L.A., van Zonneveld, M., Senturk, H., Zeuzem, S., Akarca, U., Cakaloglu, Y., …, Schalm, S.W., Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365:9454 (2005), 123–129 Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15639293&query_hl=9.
17. Kao, J.-H., Chen, P.-J., Lai, M.-Y., Chen, D.-S., Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118:3 (2000), 554–559 Retrieved from http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=10702206 http://www.gastrojournal.org/cgi/content/full/118/3/554 http://www.gastrojournal.org/cgi/content/abstract/118/3/554.
18. Lee, Y.B., Lee, J.H., Lee, D.H., Cho, H., Ahn, H., Choi, W.M., …, Lee, H.S., Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains. Antimicrob. Agents Chemother. 58:11 (2014), 6710–6716, 10.1128/AAC.03845-14.
19. Liaw, Y.F., Gane, E., Leung, N., Zeuzem, S., Wang, Y., Lai, C.L., …, Naoumov, N.V., 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136:2 (2009), 486–495 Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19027013.
20. Lim, Y.S., Yoo, B.C., Byun, K.S., Kwon, S.Y., Kim, Y.J., An, J., …, Lee, Y.S., Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut 65:6 (2016), 1042–1051, 10.1136/gutjnl-2014-308435.
21. Liu, Y., Corsa, A.C., Buti, M., Cathcart, A.L., Flaherty, J.F., Miller, M.D., …, Gane, E.J., No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. J. Viral Hepat., 2016, 10.1111/jvh.12613.
22. Liu, Y., Miller, M.D., Kitrinos, K.M., HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D. Liver Int., 2013, 10.1111/liv.12343.
23. Lok, A.S.F., Lai, C.-L., Leung, N., Yao, G.-B., Cui, Z.-Y., Schiff, E.R., …, Castiglia, M., Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:6 (2003), 1714–1722.
24. Marcellin, P., Chang, T.-T., Lim, S.G., Tong, M.J., Sievert, W., Shiffman, M.L., for the Adefovir Dipivoxil 437 Study Group, Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 348:9 (2003), 808–816.
25. Marcellin, P., Chang, T.T., Lim, S.G., Sievert, W., Tong, M., Arterburn, S., …, Rousseau, F., Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 48:3 (2008), 750–758 Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18752330.
26. Marcellin, P., Heathcote, E., Buti, M., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 359:23 (2008), 2442–2455.
27. Mills, A., Arribas, J.R., Andrade-Villanueva, J., DiPerri, G., Van Lunzen, J., Koenig, E., …, team, G.-U., Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infecious Dis. 16:1 (2016), 43–52, 10.1016/S1473-3099(15)00348-5.
28. Norder, H., Couroucé, A.-M., Magnius, L.O., Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 198 (1994), 489–503.
29. Patterson, S.J., George, J., Strasser, S.I., Lee, A.U., Sievert, W., Nicoll, A.J., …, Angus, P.W., Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 60 (2011), 247–254 Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21036792.
30. Qi, X., Xiong, S., Yang, H., Miller, M., Delaney, W.E. IV, In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir. Ther. 12:3 (2007), 355–362.
31. Sax, P.E., Wohl, D., Yin, M.T., Post, F., DeJesus, E., Saag, M., …, Team, G.-U.-S., Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet 385 (2015), 2606–2615, 10.1016/S0140-6736(15)60616-X.
32. Sax, P.E., Zolopa, A., Brar, I., Elion, R., Ortiz, R., Post, F., …, McCallister, S., Tenofovir alafenamide vs. Tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J. Acquir. Immune Defic. Syndromes (JAIDS) 67:1 (2014), 52–58, 10.1097/QAI.0000000000000225.
33. Stuyver, L., De Gendt, S., Van Geyt, C., Zoulim, F., Fried, M., Schinazi, R.F., Rossau, R., A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J. General Virology 81:Pt 1 (2000), 67–74 Retrieved from http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&dopt=r&uid=10640543 http://vir.sgmjournals.org/cgi/content/full/81/1/67 http://vir.sgmjournals.org/cgi/content/abstract/81/1/67.
34. Tenney, D.J., Genotypic determinants and phenotypic properties of antiviral-resistant HBV variants: insight from entecavir resistance studies. Antivir. Ther. 15:3 Pt B (2010), 529–535, 10.3851/IMP1504.
35. Tenney, D.J., Rose, R.E., Baldick, C.J., Pokornowski, K.A., Eggers, B.J., Fang, J., …, Colonno, R.J., Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49:5 (2009), 1503–1514 Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19280622.
36. Westland, C., Delaney, W. IV, Yang, H., Chen, S.-S., Marcellin, P., Hadziyannis, S., …, Xiong, S., Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology 125:1 (2003), 107–116.
37. Wohl, D., Oka, S., Clumeck, N., Clarke, A., Brinson, C., Stephens, J., …, Study, T., Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J. Acquir. Immune Defic. Syndromes (JAIDS) 72:1 (2016), 58–64, 10.1097/QAI.0000000000000940.
38. Yang, H., Qi, X., Sabogal, A., Miller, M., Xiong, S., Delaney, W.E. IV, Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir. Ther. 10:5 (2005), 625–633 Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16152756.
39. Yang, H., Westland, C., Xiong, S., Delaney, W.E. IV, In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. Antivir. Res. 61:1 (2004), 27–36.
40. Yuen, M.-F., Wong, D.K.-H., Sablon, E., Yuan, H.-J., Sum, S.-M., Hui, C.-K., …, Lai, C.-L., Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir. Ther. 8:6 (2003), 531–534.
41. Zhu, Y., Curtis, M., Borroto-Esoda, K., HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays. J. Virological Methods 173:2 (2011), 340–346, 10.1016/j.jviromet.2011.03.006.
42. Zhu, Y., Curtis, M., Snow-Lampart, A., Yang, H., Delaney, W., Miller, M.D., Borroto-Esoda, K., In vitro drug susceptibility analysis of HBV clinical quasi-species populations. J. Clin. Microbiol. 45:10 (2007), 3335–3341.